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Abstract Hypovitaminosis D is currently one of the most
studied environmental risk factors for multiple sclerosis
(MS) and is potentially the most promising in terms of new
clinical implications. These practical consequences, which
could be applied to MS patients without further delay,
constitute the main purpose of this review. Vitamin D is
involved in a number of important general actions, which
were not even suspected until quite recently. In particular,
this vitamin could play an immunomodulatory role in the
central nervous system. Many and varied arguments sup-
port a significant role for vitamin D in MS. In animal
studies, vitamin D prevents and improves experimental
autoimmune encephalomyelitis. Epidemiologically, lati-
tude, past exposure to sun and the serum level of vitamin D
influence the risk of MS, with, furthermore, significant
links existing between these different factors. Clinically,
most MS patients have low serum levels of vitamin D and
are in a state of insufficiency or even deficiency compared
to the international norm, which has been established on a
metabolic basis. Large therapeutic trials using vitamin D
are still lacking but the first results of phase I/II studies are
promising. In the meantime, while awaiting the results of
future therapeutic trials, it can no longer be ignored that
many MS patients have a lack of vitamin D, which could
be detected by a serum titration and corrected using an
appropriate vitamin D supplementation in order to restore
their serum level to within the normal range. From a purely
medical point of view, vitamin D supplementation appears
in this light to be unavoidable in order to improve the
general state of these patients. Furthermore, it cannot cur-
rently be ruled out that this supplementation could also be
neurologically beneficial.
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Introduction
Risk factors for MS are becoming clearer even if the
mechanisms leading from these risk factors to the disease
itself remain obscure. There are two main types of risk
factors for MS, i.e. genetic and environmental, likely with
complex interactions between them and effects which may
be deleterious or protective, depending on the case [37].
Genetic risk factors are numerous [56, 99], but they are still
relatively not well known and will not be dealt with here.
Three environmental risk factors have recently emerged
from the literature [5–7, 34, 54, 62, 92, 93]—i.e. hypovi-
taminosis D, past infection with Epstein-Barr virus (EBV)
and smoking—with effects that could be cumulative [46,
53]. In this review, we shall confine our analysis to
hypovitaminosis D, which is the risk factor currently the
most promising in terms of immediate clinical
implications.
Hypovitaminosis D has long been suspected of being a
risk factor for MS but there has recently been a sharp
increase of interest in this factor [12, 35, 44, 45, 60, 83,
116]. The putative protective role of vitamin D in MS is
based on a wide-ranging series of arguments (Fig. 1a–c).
The first group of arguments exists outside, or indeed
before, the disease, including physiological, metabolic,
experimental and immunological factors, in addition to
which there are epidemiological data on the effects of
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latitude, past exposure to sunlight and serum vitamin D
levels on the risk of MS in the general population. The
second group of arguments stems from data on MS patients
derived from biological and therapeutic studies. We shall
begin by looking at how these very diverse experimental
and epidemiological arguments have progressively accu-
mulated to strengthen the hypothesis that vitamin D plays a
substantial protective role in MS. Then, even though there
is no incontrovertible evidence from clinical studies to
confirm that vitamin D can also have a curative effect, in
the last chapter we shall propose the clinical applications
that it would appear could be made available to MS
patients without further delay (Fig. 1d). This paper is, to
our knowledge, the first proposing such practical measures
after the recent information reported on vitamin D in MS.
Rationale
Physiological and metabolic basis
Vitamin D is a steroidal hormone metabolised successively
in the skin (by sunlight or ultraviolet B rays), the liver and
the kidneys to the active metabolite 1.25-dihydroxyvitamin
D3 (calcitriol), which has a half life of several hours. This
metabolite is recognised by tissues containing specific
vitamin D receptors which are present in many parts of the
body: skin, bone, muscles, gonads, intestine, central ner-
vous system (CNS), microglia, activated monocytes and B
and T lymphocytes [23, 49–51, 69]. In addition to its well
known action on calcium and phosphorus metabolism,
vitamin D seems to have other important general effects, in
particular anti-inflammatory and antiproliferative, and also
modulatory effects on neurotrophins, growth factors and
neurotransmitters in the CNS of mammals. Daily vitamin D
requirements have recently been re-evaluated and are at
least 2,000 IU/d, which is far higher than was thought
necessary up until a few years ago [47, 52, 126, 127].
Vitamin D intake via (non-enriched) food is marginal in
western diets, generally providing less than 100 IU/d,
which is far below the daily requirement, and even Scan-
dinavian diets (rich in oily fish) scarcely exceed a few
hundred IU/d [76]. Sunshine therefore remains the princi-
pal natural source of vitamin D, providing approximately
90% of requirements. Although sunbathing can provide
10,000–20,000 IU in 15–30 min, this supply disappears
within a few weeks and cannot readily be replenished
throughout the year except in tropical countries [52, 127].
Moreover, the elderly, regardless of origin, and dark-
skinned subjects, regardless of age, are less able to syn-
thesise vitamin D than young, light-skinned subjects, who,
if they protect themselves too much from the sun (by
clothing or a sun block) may also rapidly find themselves in
a state of vitamin D insufficiency. Lastly, women generally
have lower serum levels than men [132, 133] and when
pregnant or breast-feeding their vitamin D requirement is
higher, which is, at the current time, rarely compensated
for [23, 130].
The serum component of vitamin D usually measured is
25-hydroxyvitamin D (with a half life of several weeks),
which is representative of an individual’s overall vitamin D
status [107, 134, 135]. The official international standard
for serum 25-hydroxyvitamin D levels has been established
on a physiological basis, mainly from calcium metabolism,
since it is difficult to use control groups in the general
population of temperate countries where most people could
in fact be in a state of vitamin D insufficiency in the
Fig. 1 Types of studies
supporting a role of vitamin D
in MS
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absolute, in particular in winter (see below). The interna-
tionally accepted norms fall between 75 and 200 nmol/l,
with insufficiency existing below 75 nmol/l and deficiency
below 25 nmol/l [10, 25, 38, 52, 69, 96, 107, 125, 135].
The 75 nmol/l lower limit has not been arbitrarily estab-
lished: it corresponds to the serum level below which the
parathyroid hormone is stimulated by the lack of vitamin D
and below which osteoporosis and pathological fractures
become frequent. In fact, the current usual recommenda-
tions [38, 48, 52, 88, 107, 128, 135] suggest that a blood
level of at least 90 or 100 nmol/l is needed first to optimise
calcium and phosphorus metabolism (to reduce osteopo-
rosis and to protect against pathological fractures), but also
to improve the prevention of several major autoimmune
diseases (diabetes, MS, lupus, rheumatoid arthritis etc.),
three major cancers (colon, breast, prostate) and other
common syndromes (asthenia, depression, hypertension)
and infections in general, all of which are pathologies in
which there has recently been an upsurge of studies
implicating vitamin D. On these physiological grounds it
can be deduced that vitamin D is most likely involved in a
number of general regulatory activities, over and above
calcium and phosphorus metabolism, and could have a
notable immunological role to play, in particular within the
CNS. One might also suspect that a vitamin D insufficiency
or deficiency could exist whenever there is a shortage of
sunlight, whether for an entire population—deprived of
sunshine for reasons of climate—or for a given individual
spending little or no time in the sun.
Experimental and immunological studies
There is a long-standing body of experimental evidence—
constantly being added to and now quite extensive—in
favour of vitamin D having a marked role in experimental
autoimmune encephalitis (EAE). Furthermore, many recent
immunological studies suggest that this role could be anti-
inflammatory and immunomodulatory. Vitamin D clearly
prevents the induction of EAE if administered before the
triggering of the disease and noticeably improves clinical
signs in affected mice if it is administered afterwards, thus
having a significant effect that is both protective and
curative[9, 11, 14, 15, 17, 19, 32, 67, 78, 79, 82, 84–86, 90,
102, 108, 110, 121]. This action is reported to be more
marked in female mice than in male mice, due to the po-
tentialisation of vitamin D by oestrogen [108]. It should be
noted that a potentialisation of this type has also been
reported in non-menopausal women [113, 123]. In EAE,
vitamin D could have an anti-inflammatory effect [109] by
reducing macrophages [84] and/or by regulating certain
cytokines [18, 90, 110], and/or a protective effect on
myelin by activating oligodendrocytes [23] and/or an
immunomodulatory effect on T lymphocytes by inhibiting
Th1 development and increasing Th 2 and Tr (regulatory
T) lymphocyte restoration [14, 16, 77, 82, 102]. The latter
effect (while not ruling out the others) currently seems the
most well-founded, with vitamin D consequently having a
mode of action that might be close to that of interferon b,
the beneficial effect of which in EAE is indeed potentiated
by vitamin D [122]. Lastly, in patients with MS, it has
recently been suggested that vitamin D also has a beneficial
effect on Tr lymphocytes [24, 97]. Even if EAE is not
exactly the same as MS, all these results, taken together,
constitute a solid experimental basis that supports the
existence of a marked immunological effect of vitamin D
in this pathological field.
Epidemiological studies
There are now quite a number of epidemiological studies
using a variety of different approaches suggesting a link
between latitude, exposure to sun, vitamin D and MS
(Fig. 2): (1) if we acknowledge that latitude influences the
prevalence of MS, which is universally accepted, (2) if we
note that latitude has an overall influence on the amount of
sunlight in a given region, which is a geographical reality,
(3) if we know that the level of exposure to sunlight
directly affects the serum vitamin D level, which is phys-
iologically indisputable, (4) if we add to these accepted
facts that the latitude and the mean serum vitamin D level
in the general population are correlated, (5) if we also
consider that the level of exposure to sunlight does indeed
influence the risk of MS, which has been widely reported,
and, lastly, (6) if we accept that even the blood level of
vitamin D can affect the risk of MS, which has also been
reported, albeit in a rather limited fashion—all these links
being reviewed in the following paragraphs—it is a rea-
sonable hypothesis that latitude influences the risk of MS
through the level of exposure to sunlight and the serum
vitamin D level. While one can always argue that (a) there
Fig. 2 Environmental epidemiological studies (numbers: see text)
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are too many uncertain conditions surrounding such a
theory, that (b) the methodologies are not wholly satis-
factory for this or that type of study, that (c) there seems to
be insufficient evidence for this or that type of study, or
else, for those studies that got past the previous criteria,
that (d) there are also perhaps associated or confounding
factors, the truth remains that it is currently not possible to
put forward an alternative hypothesis that is as simple,
global and logical as that of a protective role of vitamin D
in MS to explain all these facts and results, an argument
that is admittedly not proof in itself but nonetheless
strongly supports the validity of such a hypothesis.
Effect of latitude on the prevalence of MS
Latitude has an undisputed effect on the prevalence of MS,
which increases with distance from the equator, in both the
northern and southern hemispheres, at a world level [31], at
a continental level, as in Europe [65, 91], as well as in very
large countries, such as the USA [66] and Australia [117],
and even in smaller countries, such as New Zealand [112]
or France [30, 129]. In contrast, very low prevalences of
MS are observed in tropical regions, for example in
Ecuador [1], even though the protective effect of such
regions appears to be nowadays slightly attenuated, likely
due to changes in life style [3]. One can also see—at
comparable latitudes—that the degree of sunlight in a
given region or type of habitat (e.g., in Switzerland, in the
mountains compared to lowland areas) is correlated with
the prevalence of MS [64, 116, 119, 120]. It should also be
noted that emigration after the age of 15–20 years has
varying effects on immigrants depending on the direction
of emigration: if it is from a region with a high prevalence
of MS to a region of low prevalence, immigrants tend to
acquire the low prevalence of the region to which they have
emigrated (thereby losing the high risk of their region of
origin), whereas in the opposite direction, when they move
from a region with a low prevalence of MS to a region of
high prevalence, they retain the low risk of their region of
origin, at least for themselves, but not for their children, in
whom one observes the same prevalence as that of the
inhabitants of their host region [27–29, 31, 41, 66]. Only
environmental (non-genetic) risk factors can explain these
differences in prevalence between the new immigrants and
their children. As for the difference in effect on the prev-
alence of MS according to the direction of emigration, this
could be due to protective environmental factors of coun-
tries with a low prevalence of MS, which also happen to be
those with (a) the most sun but also (b) the least ‘hygiene’
in its broadest sense, due to (1a) the sustained protective
action of past exposure to sunlight (see below) received in
these countries during childhood, which could persist after
emigration to a country with less sun, and/or (1b) a
subsequent, relatively protective effect of diverse infec-
tions contracted during childhood in countries with a low
prevalence of MS (the so-called ‘hygiene hypothesis’), and
(2) the permanent and immediate protective effect of a
country with a sunny climate if one has moved there before
the normal age of onset of MS (i.e. in young adults) [5–7].
In sum, even if the effects of migration make it a little more
difficult to interpret the role of latitude in MS risk, they do
make it possible to suspect the involvement of several
environmental risk factors—possibly including infectious
factors—to explain these effects.
Effect of latitude on serum vitamin D levels
in the general population
At this point in the discussion, it is appropriate to analyse
the effects of latitude on vitamin D status in the general
population. Numerous studies have shown that on average
vitamin D levels are too low—in other words below the
normal range, which has been established on a metabolic
basis (see above)—in the adult population of all temperate
countries where they have been studied: for example, in the
USA, 74 nmol/l in a cohort from 1988 to 1994
(n = 15,000) [133] declining to 60 nmol/l in a cohort from
2000 to 2004 (n = 18,558) [33, 71]; between 75 and
51 nmol/l in Australia, depending on the region
(n = 1,398) [119]; 51 nmol/l in the United Kingdom
(n = 7,437), with a north-south gradient [55]; 49 nmol/l in
New Zealand (n = 2,900) [95]; 61 nmol/l in southern
Canada (n = 188) [98]; and 61 nmol/l in France
(n = 1,579) [22]. It should be noted that the serum levels
were determined in different seasons of the year in four of
these studies and that on each occasion the levels in winter
were 20–30 nmol/l lower than those in summer (Australia,
United Kingdom, New Zealand and Canada). In France, the
study related to nine different regions during the winter of
1994–1995. The lowest serum levels were observed in the
north (43 nmol/l) and north-east (53 nmol/l) and the
highest in the south (81 nmol/l) and south-west (94 nmol/
l), with significant correlations existing between these
levels and both latitude (P \ 0.01) and amount of sunshine
(P = 0.003) [22]. In all these temperate countries, it was
emphasised that such very low average levels of vitamin D
raise serious public health issues and that there is an urgent
need for national heath authorities to take preventive
measures [38, 39], leading for example to vitamin D sup-
plementation for all subjects in a state of insufficiency [20].
It should also be noted that rickets in very young children
and osteomalacia in the elderly are nowadays generally
well prevented in developed countries by paediatricians
and geriatricians, who preventively treat their patients
quasi systematically with vitamin D, whereas, between
these two extremities of life, little interest is shown in the
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vitamin D status of older children, adolescents and adults,
probably on the assumption that in the great majority of
cases it is normal; in fact, all recent epidemiological studies
performed in medium or high latitude countries have
shown that this is not at all the case (see above), which is
potentially prejudicial for all people in these age-groups,
not protected from hypovitaminosis D and its consequences
in terms of increased risk of multiple, serious general
affections, possibly including MS.
Looking now at a worldwide level, a correlation was
found between latitude and the serum vitamin D level in
Caucasian adult subjects in a recent meta-analysis covering
394 studies [40]. Generally speaking, Nordic countries
have even lower vitamin D levels than those in temperate
countries—e.g. 44 nmol/l in summer and 24 nmol/l in
winter in Finland (n = 220 young men) [115], and
29 nmol/l in winter in several countries of northern Europe
(n = 199 adolescent girls) [4]—whereas tropical countries
have far higher levels, e.g. 105 nmol/l in women and
168 nmol/l in men in Thailand (n = 158 adults) [21], and
more than 100 nmol/l in several groups of children and
adolescents in Brazil, including poorly nourished groups
(n = 638) [68]. In another meta-analysis relating to Europe
and Asia, it was stated that the factors affecting the serum
vitamin D level in adults are age, sex, skin colour, type of
clothing (wearing a veil leads almost systematically to
insufficiency or deficiency), food (whether or not supple-
mented with vitamin D) and the degree of urbanisation
[70]. Overall, the mean serum vitamin D level in the
general population is therefore correlated with latitude and
the amount of sunlight, whether one considers the world as
a whole or one considers a relatively small country such as
France. We can therefore see that there are links between
latitude and the prevalence of MS on the one hand and
between latitude, amount of sunlight and the serum vitamin
D level in the general population on the other hand (Fig. 3).
To complete this chain of cause and effect, we need to
establish a link between the level of sunlight and the risk of
MS, and then between the serum vitamin D level and the
risk of MS. These will be dealt with in the following two
paragraphs.
Effect of exposure to sunlight on the risk of MS
Based on a study of 136 MS patients and 272 control
subjects in Tasmania, the risk of MS was found to be lower
in those who in their childhood had been exposed to sun-
light during their holidays and weekends than in those who
had not benefited from such exposure (P \ 0.01), a finding
that was also correlated with the degree of actinic damage
to their skin (an indicator of cumulative sun exposure,
measured on the back of the hand) (P \ 0.01) [118]. A
similar result was found for the risk of CIS in Australia,
which was correlated with past exposure to sun, actinic
damage and latitude [72]. Inverse correlations between the
risk of MS and past exposure to sunlight have also been
reported in the USA [2], Norway [59] Canada [101] and
Australia [26], with, furthermore, probable genetic regu-
lation in the latter case. Lastly, in the USA, based on 79
monozygotic pairs of twins, one in each pair having MS
and the other not and both twins being different in terms of
exposure to the sun during their childhood (assessed on the
basis of nine different activities implying sun exposure), it
was shown that the twins who did not have MS were also
those who had had significantly higher past exposure to the
sun [57]. This result is particularly important because each
pair of twins had the same genetic material and, apart from
exposure to the sun, identical environmental constants
(residence, food, etc.). In sum, the level of past exposure to
the sun does indeed seem to play a role in the risk of MS.
Effect of the serum vitamin D level in the general
population on the risk of MS
To date, only one study has directly analysed the risk of
MS based on the serum level of 25-hydroxyvitamin D in
normal subjects before MS occurred in some of them. The
study, which appears methodologically sound, is therefore
extremely important since it now indicates a direct link
between the level of vitamin D circulating in the blood and
the disease, without having to rely on the effect of latitude
or sun exposure [81]. The study included 257 cases of MS
that occurred in young American soldiers (148 white and
77 black), and 514 control subjects, who had given at least
one serum sample before the onset of any neurological
Fig. 3 Correlation (performed by the author of the present article)
between the average serum levels of vitamin D in the general
population of nine French regions and the MS prevalence in roughly
analogous regions: data from Chapuy et al. [22] and Vukusic et al.
[129], Pearson test (r -0.790, P \ 0.01)
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symptoms during their military service. For the white
subjects, 5 subgroups were defined according to the serum
level of vitamin D: the subgroup with the highest—in fact
normal—levels of vitamin D (between 99 and 152 nmol/l)
had a significantly lower risk of MS than the subgroup with
the lowest levels (between 15 and 63 nmol/l) (P \ 0.01);
for the less numerous black subjects, the results were not
significant between the three defined subgroups, but the
serum levels were much lower (not exceeding 99 nmol/l)
with, therefore, a much smaller range of serum levels
between the different subgroups than for the white subjects.
It was concluded in this study that a relatively high serum
vitamin D level (though still within the normal range) is
associated with a lower risk of MS in white subjects. On
the basis of this study, Ascherio and Munger [6] have
estimated that almost three-quarters of MS cases might be
avoided if the serum levels of vitamin D were maintained
above 100 nmol/l during childhood and adolescence in the
general population. Furthermore, the fact that there is a
correlation between the mean levels of vitamin D in the
general population in regions of France and the prevalence
of MS in these regions (Fig. 3) establishes an additional
link between serum vitamin D level and the risk of MS.
Lastly, we must also cite studies where the supposed high
oral intake of vitamin D, in the form of oily fish [58, 59] or
vitamin supplements [80], decreased the risk of MS. The
overall conclusion of these epidemiological studies is that
it seems at least possible and already likely (see above) that
there are links of causality between latitude, exposure to
sun, serum vitamin D level and the risk of MS, in other
words that the last link in this chain of influences, i.e. the
one that is essential since it directly relates the organism to
variations in the external environment, is vitamin D. This
point of view, already proposed more than 35 years ago
[35], now appears to be supported by numerous convergent
experimental and epidemiological findings.
Clinical studies
Clinical studies on vitamin D in patients with MS have not
yet achieved the same level of statistical power as exper-
imental and epidemiological studies, but they are begin-
ning to accumulate and, in the great majority of cases, their
results are along the same lines, namely that vitamin D has
a probable role in MS.
Biological studies related to vitamin D in MS
In a relatively old American study, it was shown that the
mean level of 25-hydroxyvitamin D was very low
(42 nmol/l) in 80 hospitalised female MS patients (mean
EDSS: 7.2) [87], but the very lack of mobility of these
patients (virtually no longer going outdoors) could in large
part explain this result. Of far greater interest is a recent
Finnish study on a group of 40 patients at the onset of MS
(mean EDSS: 1.5) in whom serum levels were significantly
reduced in summer (55 nmol/l) compared to a control
group (80 nmol/l) [105]. Both patients and control subjects
had low levels in winter (between 40 and 50 nmol/l),
without any marked difference, but we may consider that
such low levels in winter are abnormal and prejudicial to
all. Furthermore, in three different studies, patients had
significantly lower levels during relapses than at other
times [24, 105, 106]. In an Irish study, no differences were
observed between the serum levels of patients with MS and
control subjects, but the two groups were recruited in
winter, with serum levels that were slightly low (67 and
69 nmol/l) compared to the normal range [8]. In several
other studies, serum vitamin D levels in MS patients were
significantly reduced when compared to control subjects
[24, 42, 73, 120] or to internationally accepted norms [74],
or an inverse correlation was found between vitamin D
level and either the EDSS [63, 103] or the relapse rate
[114]. Other studies raised the question of a genetic regu-
lation of vitamin D metabolism in patients with MS [89,
104], in particular in the HLA system [94], and of an
influence of a vitamin D receptor gene polymorphism on
disability [75, 111]. Lastly, as an illustration of vitamin D
level in MS, out of 167 consecutive outpatients with a
relapsing-remitting form of MS referred to a Parisian
hospital between June 2008 and February 2009, 83% were
found to have a vitamin D insufficiency (with levels of 25-
hydroxyvitamin D below 75 nmol/l), with 17% in a state of
deficiency (\25 nmol/l), and 95% did not reach the cur-
rently recommended level of 100 nmol/l, with a general
mean of 52 nmol/l (Fig. 4, unpublished personal data).
These different studies, which of course need to be con-
firmed, nevertheless already strongly suggest that most
patients with MS have serum vitamin D levels that are too
low when compared to the current norms. It should also be
added that a good proportion of MS patients with vitamin
D insufficiency have little or no disability and that one can
(1) neither attribute the vitamin D insufficiency to a
reduced mobility in these patients, (2) nor roughly predict
the vitamin D status of individuals on the basis of their
disability. It is nevertheless true that disability, by reducing
the opportunities for going outdoors, as well as systemat-
ically avoiding heat—and therefore the sun—in a good
many symptomatic MS patients (able or disabled) [100] are
factors that can exacerbate an initial hypovitaminosis D.
Accordingly, although it may be still difficult to accept that
a major and previously unsuspected problem of hypovita-
minosis D exists in MS patients, it should nevertheless be
realised that these patients are at least as lacking in vitamin
D as the general population, and maybe even a little more,
although this latter point requires further studies.
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Effect of vitamin D treatment in MS
Studies on the use of vitamin D in MS are still rare and
limited in scope. After a two-year course of treatment with
vitamin D (5,000 IU/d in the form of cod liver oil), 10
patients with MS had a 60% reduction in the predicted
number of relapses, but there was no control group [36]. In
another uncontrolled study, 15 patients who received
100 IU/d for 48 weeks experienced a 50% reduction in
relapses [131]. In a study on 39 patients with MS (17
treated with 1,000 IU/d of vitamin D3 (cholecalciferol) for
6 months and 22 control subjects), the treated patients had
a significantly increased level of TGF-b1, an anti-inflam-
matory cytokine affected by vitamin D in EAE [73]. Lastly,
a Canadian team recently demonstrated that the use of high
doses of vitamin D3 (cholecalciferol, 14,000 IU/d) during a
long period (6 months–1 year) did not induce hypercalca-
emia or notable side-effects, despite serum vitamin D
levels of nearly 400 nmol/l [61]. After 1 year of such
treatment, a 41% reduction in the number of relapses and a
significant improvement in EDSS was observed in the
treated patients (n = 25 vs. 24 untreated patients) [13]. The
results of these methodologically weak studies do not of
course allow us to draw any definite conclusions. However,
taking into account the full scientific context, they are
encouraging and provide ample justification for much more
extensive therapeutic trials (phase II or phase III). The
appropriate vitamin D doses will, however, have to be
determined, since the daily dosages in the aforementioned
four studies were 100, 1000, 5,000 and 14,000 IU/d, a
situation that raises the perplexing question of the useful
therapeutic dosage.
Questions and practical clinical approach to vitamin D
in MS
While awaiting the results of future large-scale therapeutic
studies using vitamin D, which will take several years to
complete, we can already put forward several questions on
the subject of vitamin D in MS (Fig. 1). Does vitamin D
have a protective role in MS? We can either reply straight
away in the affirmative if we consider that the physiolog-
ical and experimental arguments and the epidemiological
studies have already provided a sufficient level of proba-
bility, or we can, rather, remain skeptical and wait for
other, more convincing studies. Yet, a negative response to
such a question would appear to be untenable in the light of
the data already available. Does vitamin D have a role to
play in influencing the progression of MS once the disease
has started? The answer to this second question depends on
the results of the clinical studies already undertaken in MS,
which are still limited as regards serum vitamin D levels
Fig. 4 Serum levels of 25-hydroxyvitamin D in a Paris cohort of
patients with MS (unpublished personal data): 167 consecutive
outpatients with a relapsing-remitting form referred to Salpeˆtrie`re
hospital between June 2008 and February 2009, most of them already
being treated with the usual preventive MS therapies (interferons b,
glatiramer acetate or natalizumab), but none being supplemented with
vitamin D at the time of the titration; 118 W and 49 M; mean age:
38 years; mean EDSS: 2.5; mean annualized relapse rate: 0.45; mean
duration of disease: 6.1 years. Note that the international norm for 25-
hydroxyvitamin D serum level is between 75 and 200 nmol/l, but that
the recommended lower limit is nowadays close to 100 nmol/l (see
text)
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and remain in the embryonic state in terms of therapeutic
applications. Consequently, if at present we do not wish to
reply to this question in either the affirmative or the neg-
ative, we can remain in a state of expectation. However, the
first two questions lead inevitably to a third question.
Should the serum level in vitamin D of patients with MS be
systematically tested? If the answer to the first two ques-
tions was not in the negative, the answer to this third
question must inevitably be in the affirmative. In fact, it is
no longer the specifically neurological—and still uncer-
tain—aspect of these questions that is being raised here but
rather a general and already far better documented medical
issue. Indeed, multiple studies—even if we only take into
account those that have actually been published—suggest
that a majority of patients with MS have a vitamin D
insufficiency, a good number of whom are even in a state
of deficiency. Moreover, this insufficiency could be even
slightly more marked than that already existing in the
general population. From a purely medical point of view,
we cannot ignore that a vitamin insufficiency or deficiency
existing in the absolute is, at the very least, detrimental to
the general health of these patients. This point should be
considered by itself right now and uncoupled both from
any possible, additional specific neurological aspects and
from the more global problem of hypovitaminosis D
existing in the general population, both questions which
should and will be dealt with separately in the immediate
future.
After the serum titration of vitamin D, it appears
useful to supplement patients who are in a state of
insufficiency [24]. This should involve MS patients at all
stages of the disease, but could also include patients who
are at the CIS stage or even before this stage (i.e. with
‘pre-CIS’, based solely on magnetic resonance imaging
criteria), in an attempt also to achieve maximal possible
protection of patients who are still at the very beginning
of an abnormal inflammatory process. However, for all
these patients with a lack of vitamin D, the main aim of
supplementation would, at present, be a general medical
one, namely simply to increase serum concentrations to
the currently recommended normal level, i.e. in the
region of 100 nmol/l (see above): this would mean
administering between 1,000 and 3,000 IU of vitamin D3
(cholecalciferol) on average per day (using either daily
or monthly intakes), adjusted according to the initial
serum concentration [47, 52, 107, 124, 126, 128]. This
measure should already improve the general health of
patients with vitamin D insufficiency or deficiency by
normalising calcium and phosphorus metabolism, but
perhaps also by reducing asthenia, optimising muscle
strength, reducing susceptibility to various infections,
having a beneficial effect on thymic status, etc. Fur-
thermore, it cannot currently be ruled out that relatively
moderate doses of vitamin D—precisely such as those
used to bring the serum level up to normality—can also
have a favourable effect on the progression of the neu-
rological disease itself, including at its earliest stages
(CIS and pre-CIS). Lastly, it is important before starting
the treatment to check that there is no hypercalcaemia
(which may exceptionally be present) and after several
months to monitor the serum vitamin D level and
calcaemia, so that the daily dosage can be adjusted if
necessary. There is no need to fear vitamin D intoxica-
tion—an unfounded myth—or hypercalcaemia during the
treatment (1) if the patient has normal (or low) calca-
emia before starting the treatment, (2) if one uses 25-
hydroxyvitamin D3 (cholecalciferol) and not 1,25-di-
hydroxyvitamin D3 (calcitriol), with, moreover, (3) doses
of less than 10,000 IU/d [43, 124, 127]. This theoretical
upper limit (10,000 IU/d) leaves a considerable safety
margin if one uses at most a dose of 2,000 or 3,000 IU/d
simply to normalise serum concentrations. Very long-
term vitamin D treatment should be envisaged and,
where low exposure to sunlight is a constant factor,
maintained generally at the same doses, failing which the
serum concentration will return to the insufficiency zone
if the treatment is stopped or the dosage simply reduced.
In sum, this treatment, which has become mandatory
from a general medical point of view for MS patients
with a proven lack of vitamin D, can be given in
addition to the other, main preventive therapies and is in
fact simple, natural, safe and inexpensive. It could also
be useful from a neurological perspective, for the overall
progression of MS and for certain everyday symptoms.
Conclusions
Based on considerable physiological evidence, a large
body of experimental findings, consistent epidemiological
data and limited but promising clinical studies, the
hypothesis that hypovitaminosis D is one of the envi-
ronmental risk factors for MS has rapidly gained support
and could soon be confirmed by more extensive clinical
studies. Over and above its possible role in MS,
hypovitaminosis D—due to its widespread distribution
among the general population in countries with low
levels of sunlight—now raises a crucial public health
problem which must be solved if we are to achieve
optimal prevention of a number of general affections that
are common in these countries. Neurologists, like all
medical practitioners, should be keenly aware of this
problem, but those who are more particularly involved in
caring for MS patients must be doubly receptive and
rapidly preventive, since ‘time is brain’ is also applicable
to MS.
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